key: cord-0959139-x6g3kqju
authors: Bi, Chongwei; Ramos-Mandujano, Gerardo; Tian, Yeteng; Hala, Sharif; Xu, Jinna; Mfarrej, Sara; Esteban, Concepcion Rodriguez; Delicado, Estrella Nuñez; Alofi, Fadwa S.; Khogeer, Asim; Hashem, Anwar M.; Almontashiri, Naif A.M.; Pain, Arnab; Izpisua Belmonte, Juan Carlos; Li, Mo
title: Simultaneous Detection and Mutation Surveillance of SARS-CoV-2 and co-infections of multiple respiratory viruses by Rapid field-deployable sequencing
date: 2021-03-31
journal: Med (N Y)
DOI: 10.1016/j.medj.2021.03.015
sha: 0d9f4d24854afc5a95084fdec05f1436f2794013
doc_id: 959139
cord_uid: x6g3kqju

Background Strategies for monitoring the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are crucial for combating the pandemic. Detection and mutation surveillance of SARS-CoV-2 and other respiratory viruses require separate and complex workflows that rely on highly-specialized facilities, personnel, and reagents. To date, no method can rapidly diagnose multiple viral infections and determine variants in a high-throughput manner. Methods We describe a method for multiplex isothermal amplification-based sequencing and real-time analysis of multiple viral genomes, termed NIRVANA. It can simultaneously detect SARS-CoV-2, influenza A, human adenovirus, and human coronavirus, and monitor mutations for up to 96 samples in real-time. Findings NIRVANA showed high sensitivity and specificity for SARS-CoV-2 in 70 clinical samples with a detection limit of 20 viral RNA copies per μl of extracted nucleic acid. It also detected the influenza A co-infection in two samples. The variant analysis results of SARS-CoV-2 positive samples mirror the epidemiology of COVID-19. Additionally, NIRVANA could simultaneously detect SARS-CoV-2 and PMMoV (an omnipresent virus and water quality indicator) in municipal wastewater samples. Conclusions NIRVANA provides high-confidence detection of both SARS-CoV-2 and other respiratory viruses and mutation surveillance of SARS-CoV-2 on the fly. We expect it to offer a promising solution for rapid field-deployable detection and mutational surveillance of pandemic viruses. Funding M.L. is supported by KAUST Office of Sponsored Research (BAS/1/1080-01). This work is supported by KAUST Competitive Research Grant (URF/1/3412-01-01, M.L. and J.C.I.B.) and Universidad Catolica San Antonio de Murcia (J.C.I.B.). A.M.H. is supported by Saudi Ministry of Education (project 436).

infection of SARS-CoV-2 and other respiratory viruses-respiratory syncytial virus (RSV) and influenza 20 being the most common viral pathogens identified, 4,5 and influenza was particularly high in deceased 21 patients. 6 Even though the overall co-infection rate may be low, and non-COVID-19 respiratory 22 infections have experienced a sharp decline. 7 presumably due to public health interventions, the 23 detection of co-infection is potentially useful for monitoring the pandemic and may benefit how patients 24 are treated. To date, no method can rapidly diagnose multiple viral infections in a high-throughput 25 manner. Ideally, such methods should be field-deployable to allow timely assessment of outbreaks 26 anywhere anytime.

Both rRT-PCR and NGS are sophisticated techniques whose implementation is contingent on the 29 availability of highly-specialized facilities, personnel and reagents. These limitations could translate into 30 long turnaround times and inadequate access to tests, even in developed countries. To address these 31 issues, several PCR-free nucleic acid detection assays have been proposed as point-of-care replacements 32 J o u r n a l P r e -p r o o f of rRT-PCR. Chief among them is reverse transcription coupled loop-mediated isothermal amplification 1 (RT-LAMP 8 ), which has been used for rapid detection of SARS-CoV-2 RNA. 9-12 On the sequencing front, 2 the pocket-sized Oxford Nanopore MinION sequencer has been used for rapid pathogen identification in 3 the field. 13,14 Since MinION offers base calling on the fly, it is an attractive platform for consolidating viral 4 nucleic acid detection by PCR-free rapid isothermal amplification and viral mutation monitoring by 5 sequencing. However, there are several challenges for an integrated point-of-care solution based on RT-6 LAMP and Nanopore sequencing. RT-LAMP requires a complex mixture of primers that increases the 7 chance of non-specific amplification and makes it difficult to multiplex. Additionally, LAMP amplicons 8 used for SARS-CoV-2 detection are short. 10,11 Sequencing singleplex short amplicons not only fails to take 9 advantage of the long-read and sequencing throughput (~10 Gb) of the MinION flow cell, it is also prone 10 to false negative reporting due to amplification failure. Nanopore sequencing has its own caveats too.

Due to its relatively high basecalling error, new bioinformatics tools based on dedicated algorithms 15, 16 12 are also needed to accurately identify the presence of viral sequences (substituting for rRT-PCR) and 13 analyze virus mutations (substituting for NGS).

Here we developed isothermal recombinase polymerase amplification (RPA) assays to simultaneously 19 patients at a time (Fig. 1a) . We developed a bioinformatics pipeline for on-the-fly analysis to reduce the 20 time to diagnosis and sequencing cost by stopping the sequencing run when data are sufficient to 21 provide confident answers.

Singleplex RPA was first performed to test its ability to amplify the SARS-CoV-2 genome from a 25 nasopharyngeal swab sample tested positive for the virus using the US CDC assays 17 (CT value=21).

Sixteen primers were tested in 12 combinations to amplify 5 regions harboring either reported signature 27 mutations 18,19 useful for strain classification or mutation hotspots (GISAID, as of March 15, 2020). Five 28 pairs of primers showed robust amplification of DNA of predicted size (range: 194-466 bp) in a 20-min 29 isothermal reaction at 39 °C (Fig. 1b, Fig. 2a) . The specificity of all 5 RPA products was verified by 30 restriction enzyme digestion (Fig. 2b) . The limit of detection of RPA reaches below 10 copies per reaction 31 (Fig. 2c) . Furthermore, we showed that these RPA reactions could be multiplexed to amplify the five 32 J o u r n a l P r e -p r o o f regions of the SARS-CoV-2 genome in a single reaction (Fig. 1c) , thus significantly simplifying the 1 workflow.

We next performed multiplex RPA using ten SARS-CoV-2 positive samples (SARS-CoV-2 + , determined by 4 US CDC assays 17 , CT value range: 15 to 27.9). Multiplex RPA products of the 10 samples were individually 5 barcoded, pooled and prepared into a Nanopore sequencing library using an optimized protocol to save 6 time (see methods). The whole workflow from RNA to sequencing took approximately 4 hours (Fig. 1a) .

The barcoded library was sequenced on a Nanopore MinION using a R9.4.1 flow cell. After 12-h 8 sequencing, we acquired a total of 1.7 million reads from this barcoded library (Fig. S1a) . The 9 demultiplexed reads were distributed relatively evenly among the barcodes (samples). We further 10 aligned the reads to the SARS-CoV-2 reference genome and found that all RPA amplicons were covered 11 by thousands of reads in all samples, suggesting that barcoded multiplexed RPA sequencing worked 12 effectively (Fig. 1d, Fig. S1b ).

The identification of a SARS-CoV-2 positive sample can be achieved by surveying the existence of 15 targeted amplicons via sequencing. However, the determination of negative samples needs to rule out 16 potential sample collection failure, thus requiring a sample quality validation control. We used the 17 existence of transcripts of the human housekeeping gene ACTB as a quality check of sample collection.

The sequencing results showed that the ACTB gene could be effectively amplified without significantly 19 affecting the amplification of SARS-CoV-2 (Fig. S1c ).

Co-infection with other respiratory pathogens in COVID-19 patients has been evaluated, though current 22 detection of co-infections requires additional rRT-PCR assays 6,20,21 or NGS 5 . Such ad hoc tests are not 23 amenable to large-scale screening of co-infections. On the other hand, multiplexed RPA of different 24 viruses could be a promising solution to detect co-infections in a timely and efficient manner.

As a proof-of-principle of multiplex RPA of multiple human viral pathogens, we screened and validated 27 RPA primers that robustly amplify influenza A (FluA), human adenovirus (HAdV), and non-SARS-CoV-2 28 human coronavirus (HCoV), respectively (data not shown). We added the three pairs of respiratory virus 29 primers to the multiplex SARS-CoV-2 RPA panel to achieve simultaneous isothermal amplification of four 30 viral pathogens (Table S1 ). To ensure effective amplification of all targets, we adjusted the 

The presence of SARS-CoV-2 has been reported in municipal sewage, of which the viral load was found 5 to be correlated to the reported COVID-19 prevalence. 22 This suggests that wastewater surveillance 6 could be a sensitive indicator of the total COVID-19 caseload (including asymptomatic cases) in the 7 population. To evaluate the possibility of using multiplex RPA to detect SARS-CoV-2 in wastewater, we 

To simplify the interpretation of the results, RTNano provided a summary score of SARS-CoV-2 based on 6 a set of predefined rules (Table S2) 

Ten more positives were identified by RTNano (RTNano + ) as the data output increased in the next 22 18 hours of sequencing (Fig. 3b, File S1 ). An identical aliquot of each sample was analyzed in parallel using RTNano results (Fig. 3d) . Based on the N1 standard curve, we estimated the limit of detection (LoD) of 32 J o u r n a l P r e -p r o o f NIRVANA was ~29 viral RNA copies/µl of extracted nucleic acid (86 copies per reaction, based on 1 average N1 CT value of 33.37 of POS_0, and see methods), which was comparable to current rRT-PCR 2 assays. 26

We next surveyed co-infection of three common respiratory viruses in the 60 samples. FluA co-infection 5 was determined by two independent commercial rRT-PCR assays (Resp'Easy TM in vitro diagnostic kit (CE-6 IVD) and IDT influenza A,B/RSV identification kit). Four samples were identified as FluA + in both assays 7 (CT value range: 33.97 to 39.33 by Resp'Easy TM ) (Fig. S1e) . RTNano detected the FluA + sample with the 8 lowest CT value (sample 46, CT 33.97) with high confidence (Fig. 3e) . HAdVs and HCoV co-infection was 9 examined using the Resp'Easy TM kit, and only one HCoV + sample was identified (Resp'Easy TM CT=35.18).

RTNano reported no HAdVs co-infection and failed to detect the HCoV + sample. high-confidence reads mapped to the expected amplicon sequences (data not shown). Thus, we 20 concluded that these two samples were true positives. The average N1 CT value of POS_1 was improved 21 from 30.48 to 32.06 (Fig. S1f ). Using the new data, we calculated the LoD of SARS-CoV-2 of 7-amplicon 22 NIRVANA to be ~20 viral RNA copies/µl of extracted nucleic acid (61 copies per reaction, based on 23 average N1 CT value of 33.37 of POS_0). It is worth noting that the sensitivity of SARS-CoV-2 detection of 24 multi-virus multiplex NIRVANA is lower than that of singleplex rRT-PCR assays achieved in our hands. 27

Further optimization of the RPA primer combination may improve the sensitivity, and the ability of 26 NIRVANA to identify multiple viruses and to detect variants could partially offset the reduced sensitivity.

The sensitivity of FluA detection was also improved as two FluA + samples (Resp'Easy TM CT value of 33.97 29 and 36.03) were correctly identified (sample 46 & 58 in Fig. S1e, Fig. S1g ). The HCoV + sample was still not 30 identified. Since NIRVANA showed a robust ability in detecting HCoV in the positive control sample (Fig.   31 3a), we suspected that the HCoV in the clinical sample may belong to a different strain that could not be 32 J o u r n a l P r e -p r o o f amplified by our HCoV primers. Taken together, these results showed that NIRVANA provided highly-1 confident SARS-CoV-2 detection for virus loads above 20 copies/µl of extracted nucleic acid and reliable 2 detection of potential co-infections.

RTNano has an integrated function to quickly analyze variants in each sample during sequencing. We 5 used it to analyze sequence variants in ten SARS-CoV-2 positive samples (Fig. 1d) . It detected 16 single 6 nucleotide variants (SNVs) in the ten samples and all of them had been reported in GISAID (Fig. 3f, multiple primers (at least 4) to amplify one amplicon, which is a challenge to multiplexing. In contrast, 1 we showed that RPA-based NIRVANA is able to amplify and detect nine amplicons in one pot (Fig. 3a) . The whole workflow of NIRVANA can be further shortened by performing one-pot RT-RPA (Fig. 2d ) so 10 that the time from RNA to result can be as short as 3.5 hours. All molecular biology reactions in the 11 workflow can be done in a simple heating block, and all necessary supplies fit into a briefcase (Fig. S2b ).

We expect it to provide a promising solution for rapid field-deployable detection and mutational 13 surveillance of pandemic viruses. purified and prepared to the Nanopore library using an optimized barcoding library preparation protocol.

In the end, the sequencing was performed in the pocket-sized Nanopore MinION sequencer and 7 sequencing results were analyzed by our algorithm termed RTNano on the fly. Table S1 , and 2.5 µl of 5-fold diluted cDNA were 1 used as template. The FluA and HAdV primers target regions that are expected to be shared by all 2 subtypes of the corresponding viruses, while the HCoV primers are specific for the HKU1 subtype. The 3 reaction was incubated at 39 ˚C for 4 min, then vortexed and spin down briefly, followed by a 16-min 4 incubation at 39 ˚C.

Library preparation and sequencing 7 8

The RPA library preparation was done using Native barcoding expansion kit (Oxford Nanopore 9

Technologies EXP-NBD114 and EXP-NBD196) following Nanopore PCR tiling of COVID-19 Virus protocol 

The 3 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV 4 and naming it SARS-CoV-2

An Outbreak of 7 NCIP (2019-nCoV) Infection in China -Wuhan

A Genomic Perspective on the Origin and Emergence of 10 SARS-CoV-2

Co-infections in people with COVID-19: a 12 systematic review and meta-analysis

Metagenomic sequencing to detect respiratory viruses in persons 15 under investigation for COVID-19

17 High prevalence of SARS-CoV-2 and influenza A virus (H1N1) coinfection in dead patients 18 in Northeastern Iran

Precipitous Fall in Common Respiratory 20 Viral Infections During COVID-19

Loop-mediated isothermal amplification of DNA

Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using 25 Colorimetric LAMP. medRxiv

Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a 28 reverse transcription loop-mediated isothermal amplification assay

CRISPR-Cas12-based detection of SARS-CoV-2

Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv

Towards a genomics-informed, real-time, global pathogen 35 surveillance system

Rapid metagenomic identification of viral pathogens in clinical 37 samples by real-time nanopore sequencing analysis

Long-read Individual-molecule Sequencing Reveals CRISPR-induced Genetic 40 Heterogeneity in Human ESCs. bioRxiv

5: a more powerful, quicker and lighter simulator for 1 Nanopore sequencing

Division of Viral Diseases. Real-Time 4 RT-PCR Panel for Detection 2019-Novel Coronavirus

Genotyping coronavirus SARS-CoV-2: methods and implications

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-8 dependent-RNA polymerase variant

Rates of Co-infection Between 11 SARS-CoV-2 and Other Respiratory Pathogens

Coinfection of SARS-CoV-2 and Other Respiratory Pathogens

Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in 17 the Early Stage of the Epidemic in The Netherlands

Pepper mild mottle virus as a water quality 20 indicator

False-positive COVID-19 results: hidden 22 problems and costs

False-positive reverse transcriptase polymerase chain reaction screening 24 for SARS-CoV-2 in the setting of urgent head and neck surgery and otolaryngologic 25 emergencies during the pandemic: Clinical implications

Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-28 qPCR primer-probe sets

A Robust, Safe, and Scalable Magnetic Nanoparticle 31 Workflow for RNA Extraction of Pathogens from Clinical and Wastewater Samples

Clinical and virologic characteristics of the first 12 patients with coronavirus 34 disease 2019 (COVID-19) in the United States

LamPORE: rapid, accurate and highly scalable molecular screening for 37 SARS-CoV-2 infection, based on nanopore sequencing. medRxiv

Detection of noroviruses in tap water in Japan 40 by means of a new method for concentrating enteric viruses in large volumes of 41 freshwater

Minimap2: pairwise alignment for nucleotide sequences

The Sequence Alignment/Map format and SAMtools

Highlights • Multiplex isothermal amplification of viral genomes followed by Nanopore sequencing • Simultaneous detection of SARS-CoV-2 and co-infecting viruses in up to 96 patients • Simultaneous detection of SARS-CoV-2 and pepper mild mottle virus in wastewater • Real-time and field

develop a convenient sequencing-based method that can simultaneously detect SARS-CoV-2, influenza A, human adenovirus, and human coronavirus and monitor viral mutations for up to 96 samples in real-time. This rapid and field-deployable method promises to help contain the spread of COVID-19 and ensure the effectiveness of vaccines. Context and Significance It is challenging to simultaneously identify SARS-CoV-2 infection and detect viral mutations. Bi et al. develop a convenient sequencing-based method that can simultaneously detect SARS-CoV-2, influenza A, human adenovirus, and human coronavirus and monitor viral mutations for up to 96 samples in realtime. The method not only showed high sensitivity and specificity for SARS-CoV-2 in 70 clinical samples but also detected cases of influenza A co-infection